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At the 2010 Osteoarthritis Research Society International (OARSI) congress in Brussels I was asked to
present on “Biochemical Markers” in the “Year in Review” session. This provided an opportunity to
summarize ongoing work and consensus building in the osteoarthritis research community related
to osteoarthritis biomarkers, and second, and an opportunity to brieﬂy overview a subset of studies from
the previous 12 months related to soluble biomarkers that provided novel insights in the ﬁeld. This review
therefore brieﬂy summarizes the progress in 2010 of the OARSI OA Biomarkers Global Initiative and the
OARSI FDA Biomarkers Working Group, and provides a summary of selected osteoarthritis biomarker
studies reported over the previous 12 months based on a review of articles from seven musculoskeletal
journals and a PubMed search using the terms biomarkers and osteoarthritis.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The ﬁeld of osteoarthritis (OA) biochemical markers is steadily
advancing, leading to the progressive unfolding of the potential role
to be played by OA biomarkers in basic research, clinical studies and
clinical practice. The long-term goal is to advance, through clinical
qualiﬁcation, a subset of useful biomarkers from the realm of the
plausible to the realm of practical application. Increasingly the OA
disease process is being considered a continuum, beginningwith an
inciting event, such as genetic variation or injury, progressing
through molecular, pre-radiographic and radiographic stages,
culminating in end-stage disease1. With this reclassiﬁcation of the
disease process as a continuum of a series of stages, it is readily
apparent that biomarkers could play a pivotal role in disease
detection and monitoring, particularly during the critical early
molecular stages when other tools could not readily identify it.
These developments are occurring in parallel with efforts to
harness biomarkers for applications in a wide variety of diseases
and to standardize the regulatory process for biomarker qualiﬁca-
tion to accelerate development of therapies2. To put into perspec-
tive the progress on OA-related biochemical biomarkers in the past
year, I summarize here the recent history of the networking efforts
in the OA biomarkers research community, and highlight some of
the biomarker studies published in the last 12 months.to: Virginia Byers Kraus,
, NC 27710, United States.
s Research Society International. POARSI OA Biomarkers Global Initiative
The OARSI OA Biomarkers Global Initiative grew out of an NIH/
NIAMS sponsored biomarkers network of investigators and public
biomarkers research meetings funded from 2002 through 2006. In
2008 the National Institutes of Health/National Institute of Arthritis
and Musculoskeletal and Skin Diseases (NIH/NIAMS) funded support
for three OA-related biomarkers workshops to continue the investi-
gative momentum in the OA biomarker ﬁeld. A ﬁrst workshop was
held inApril, 2009 (Bethesda,MD) focusingonOA-relatedbiochemical
markers with a meeting summary published this year3. A second
workshop, focusing on OA-related genetic markers, was held in
November, 2010 (Atlanta, GA). The slides from these meetings are
available through the OARSI website (http://www.oarsi.org/) and
ameeting summary is in preparation. A thirdworkshopwill be held in
2012 focusing on OA-related imaging biomarkers. These workshops
are serving thepurpose forwhich theyweredesigned,namely, tobring
together a critical mass of OA biomarkers researchers to advance the
knowledge, qualiﬁcation, and clinical application of biomarkers in OA.OARSI FDA Biomarkers Working Group
A second major accomplishment related to OA biomarkers, to
come to fruition in 2010, has been production of a comprehensive
white paper on the “Application of Biomarkers in the Development of
Drugs Intended for the TreatmentofOsteoarthritis”by theOARSI Food
and Drug Administration (FDA) Biomarkers Working Group4. This
groupwas one of seven that dealtwith different aspects of OA, all part
of a major initiative on the part of OARSI to assist in overcoming
barriers to thedevelopmentof successful diseasemodifying agents forublished by Elsevier Ltd. All rights reserved.
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Cartilage in 2011) represent responses to queries posed by the FDA in
an effort to consider revision of guidelines for drug development.
Action items posed in thewhite paper represent a summary of critical
needs in the OA biomarkers ﬁeld as envisioned by the 20 experts of
the biomarkers working group. The white paper on biochemical
markers included recommendations on biomarker qualiﬁcation
(deﬁned as the evidentiary process of linking a biomarker with bio-
logical processes and clinical endpoints), and elucidated unmet needs
in the ﬁeld including articulating a research agenda. A few key
recommendations include the need to standardize reporting of
biomarker results, to ﬁnd minimal meaningful differences in
biomarkers in the presence and absence of a treatment, to standardize
methods of sample collection for biomarker studies (the white paper
provides an appendix with suggested methods of sample collection),
to collect information on non-signal joints in studies measuring
systemic biomarkers, to identify principal tissue sources of
a biomarker, and ﬁnally, to begin epitope mapping of biomarkers
using techniques such as mass spectroscopy (using the antibodies or
reagents speciﬁc to the particular assay). It is hoped that this white
paper will inform and facilitate the process of advancing OA
biomarkers for drug development and clinical trial applications.
Summary of selected biomarkers publications (2009e2010)
To identify OA biomarker studies for this year in review presen-
tation, I reviewed the OA biomarker studies of the past 12 months in
sevenmusculoskeletal journals (Osteoarthritis&Cartilage, Arthritis &
Rheumatism, Arthritis Care & Research, Arthritis Research & Therapy,
Annals of Rheumatic Disease, J Rheumatology, and J Orthopaedic
Research), performed a PubMed search using the query terms of
biomarkers and OA with the search limited to the prior 12 months,
and reviewed the abstracts of the 2010 World Congress on Osteoar-
thritis OARSI (Brussels). A summary of selected studies is provided in
Table I. In brief, this Table summarizes: a recent major review of
human OA biomarker studies fulﬁlling the need for a means of
comparing and contrasting various trials and biomarkers using some
speciﬁc reporting criteria5; two trials (one clinical in humans and one
preclinical animal study) addressing the need for greater inclusion of
biomarkers in OA clinical trials in order to potentiate the effective
clinical use of biomarkers in the future; ﬁve studies related to
advances with aggrecanase-generated neoepitopes providing excel-
lent examples of efforts to develop biomarker tools to facilitate dose
setting in early clinical studies and to increase conﬁdence in drug
mechanism; two studies related to prediction of incident OA
addressing the need to identify biomarkers that recognize the early
molecular stages of OA that may be most susceptible to disease
modiﬁcation6,7; four studies related to various OA disease subsets
addressing the need to study a wide variety of patient types with
varied clinical characteristics and joint-site involvement; and three
studies related to identifying the joint tissue source of a biomarker
addressing the need to understand the principle tissue source(s) of
a given biomarker as accurately as possible so that the origin(s) of the
epitope(s) is/are clearly understood.
I would like to highlight a few particulars from several of these
studies. The paper on OA biomarkers by van Spil et al.5 represents
a seminal reviewon the current qualiﬁcation status of OA biomarkers
for structure and pain outcomes. van Spil summarized biomarker
results from knee and hip OA studies (84 in all), and classiﬁed them
according to the BIPED classiﬁcation scheme8 (denoting Burden of
disease, Investigative, Prognostic, Efﬁcacy of intervention and Diag-
nostic biomarkers). Of note, the OARSI FDA initiative Biomarkers
Working Group recently expanded the acronym to BIPEDS with the
addition of a Safety biomarker category, to be able to categorize this
additional essential use and capability of biomarkers, anticipated tobe of increasing importance as the armamentarium of biomarkers
expands and becomes more sophisticated. The van Spil review was
elegantly organized, and included two monumental supplementary
tables that provide a succinct and comprehensive summary of the
vast majority of biomarker studies performed to date. The strength
(or lack thereof) of evidence for a biomarker to be classiﬁed into
a BIPED categorywas scored on a 1e2þ scale. In addition, the precise
details were provided regarding the particular assay used (e.g.,
manufacturer, antibodies, additional references, etc.), thus providing
a strong paradigm for amethod of reporting biomarker results and an
example of the level of detail that is not only useful, but increasingly
necessary, as we endeavor to further reﬁne our understanding
OA-related biomarkers and seek to apply them clinically.
Two papers provided data showing baseline biomarkers predict-
ing incident knee OAw7e10 years later6,7. I look upon these studies
as providing particularly exciting evidence to support the capability
of selecting biomarkers to detect the molecular stage of the disease
and to pave the way for gaining insights into the early molecular
stages of OA. The ﬁrst, by Ling, is a case-control study nested within
the Baltimore Longitudinal Study of Aging that included 22 incident
cases of radiographic OA (both hand and knee together) and 66 age,
sex and body mass index matched controls without radiographic
hand or kneeOA6. The samples thatwere testedwere obtained at the
time of radiographic classiﬁcation as either case or control and they
had a second sample thatwas obtained up to 10 years earlier at a time
when the participants were free of radiographic hand and knee OA,
representing pre-radiographic or molecular earlier stages of the
disease. Antibody-based microarrays, requiring only 20 mL of serum,
were used to screen 169proteins. Overall, therewere 10 differentially
expressed proteins predictive of incident OA and 16 proteins that
were signiﬁcantly different between cases and controls at the time of
classiﬁcation at follow-up diagnosis of OA. There were a total of six
‘disease initiating event’ biomarkers that were elevated and differ-
entially expressed prior to radiographic OA but that were not differ-
entially expressed at the time of prevalent OA. There were a total of
four ‘disease sustaining event’ biomarkers that were elevated both
before and at the time of radiographic OA. There were several ‘take-
home messages’ from this study: that altered extracellular matrix
catabolism plays a central role in OA initiation; that increased
expression of inﬂammatory cytokines and chemokines is associated
with prevalent OA, lending additional support to the notion of OA as
an inﬂammatory disease; and that prevalent OA is associated with
ongoing attempts at repair based on the observation of increased
expression of TIMPs and growth factors.
The second study by Golightly7, presented as a poster at OARSI
(Brussels), evaluated the predictive ability of biomarkers for incident
knee OA. There were no statistically signiﬁcant biomarker associa-
tions with incident knee OA based on using KellgreneLawrence (KL)
grading, however, serumCartilageOligomericMatrix Protein (COMP)
was highly predictive of incident osteophytes, and both COMP and
serum hyaluronan (HA) were predictive of incident joint space nar-
rowing. Itwas alsonotable thatosteophyte and joint space narrowing
were detected by different biomarkers, and as presented in the Year
in Review session by Wim van den Berg (his own work and that of
Chris Little’s), these two processes appear to involve different path-
ways, and different pathophysiologies. This suggests that these two
aspects of radiographic OA are inappropriately conﬂated by KL grade,
and in biomarker studies, analyses of these features should ideally, be
looked at individually.
Three studies addressed the effects of immobilization and
activity on biomarkers9e11 and are remarkable for their novelty and
rigor. The ﬁrst, a crossover trial of ﬁve individuals, studied the
effects of 14 days of enforced immobilization in a 6 degree ‘head-
down-tilt-bed-rest’ position, with and without two brief treat-
ments (5 min) of whole body vibration9. The 2-week periods of
Table I
Summary of select biomarker studies (2009e2010)
References Follow-up Population/controls (N) BIPEDS Results description and comments Assay
Reviews
van Spil5 N/A Review of 84 studies ALL Comprehensive review of hip and knee
OA studies that evaluated biomarkers;
this seminal work distinguishes
associations with structural vs
symptom outcomes.
See the primary article for details.
Trials
Pelletier 201015 2 years 161 knee OA patients
(81 licofelone treated,
74 naproxen treated)
P, E Clinical trial of licofelone vs naproxen; in
multivariate analyses adjusted for age, sex,
and treatment (but not BMI) baseline
lower serum MMP-1, higher MMP-3
and higher COMP predicted risk of MRI
cartilage loss in the medial, medial, and
lateral compartments respectively; adjusted
for age, sex, and treatment (but not BMI)
change in serum CRP predicted change in
medial cartilage volume loss; adjusted for
baseline biomarker level, MMP-3 increased
signiﬁcantly less over 2 years in the licofelone
compared with the naproxen group;
unadjusted for BMI, baseline CRP predicted
symptomatic response to treatment; baseline
serum CTXI correlated with increase in
size of bone marrow lesions on MRI.
Fasting serum: MMP-1, MMP-3, IL-6, CRP
(Fluorokine MAP, R&D Systems, MN,
USA); COMP (Biovendor, NC, USA);
CTXI (serum Crosslaps, IDS, Boldon, UK),
urinary CTX-II (Cartilaps, IDS, Boldon, UK).
Settle 201016 Yes e 28 days
following medial
meniscectomy
60 skeletally mature
female beagles
E A highly selective MMP-13 inhibitor exhibited
chondroprotective effects in an in vitro cartilage
explant model and in an in vivo canine medial
meniscectomy (MM) model which was reﬂected
in the media and biological samples: urinary
TIINE (type II collagen) and synovial ﬂuid aggrecan
(ARGS and AGEG epitopes) degradation
epitopes; ELISA and LC-MS/MS detected TIINE
were comparable and 2-fold increased following
MM; Neither ARGS nor AGEG were detected
in urine following MM; biomarkers PIINP and
CPII did not change in untreated control
(meniscectomized) animals; per the authors:
‘fragments of both collagen and aggrecan are
potential and possibly complementary markers
of disease progression’; nicely characterized
change in 45-mer TIINE peptides with dog age.
TIINE assayed by sandwich ELISA with
5109/9A4 monoclonal antibodies and by
LC-MS/MS; aggrecan neoepitopes by
immunoafﬁnity LC-MS/MS using BC3
anti-ARGN antibody and an in-house
anti-1772AGEG antibody; PIINP (Pﬁzer);
CPII (Ibex, Montreal, Canada).
Aggrecanase neoepitope
related
Madsen 201017 N/A In vitro bovine articular
cartilage stimulated
with cytokines
N/A In cytokine stimulated cartilage explant media,
glycosylated (ADAMTS-4 aggrecanase-generated) 3
ARGSVI fragments detected after 7 days and a
deglycosylated low-molecular weight
(MMP-generated) 342FFGVG was detected after
21 days; unable to conclude on basis of in vitro
studies whether glycosylation played an
important role in enzymatic cleavage events.
Western blots with BC3 anti-ARGSVI
antibody (Caterson 2000)18;
AF28 anti-FFGVG antibody
(Fosang 1995)19.
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de Jong 201020 N/A 32 OA and 60 RA patients I A modest but consistent antigenic response
(proliferation and cytokine production)
was observed by ex vivo stimulation of
peripheral blood mononuclear cells of RA
and OA patients with aggrecan G1 epitopes.
Serum cytokines by LabMAP Technology
(Luminex, TX, USA).
Swearingen 201013 Yes e 1 week 24 Lewis rats for 7-day
time course; w66 Lewis rats
for treatment efﬁcacy evaluation;
18 human synovial ﬂuids from time
of joint replacement for assay
speciﬁcity evaluation
E Monoiodoacetate intraarticular injection into
the rat knee resulted in a time dependent
release (over 7 days) of aggrecanase-generated
neoepitopes in synovial ﬂuid (collected by lavage)
that was inhibited in a dose-dependent
manner by an aggrecanase-inhibitor; ELISA
speciﬁcity demonstrated by peptide competition
in human synovial ﬂuid; NITEGE assay
measured bovine, human and rat aggrecan
without need for aggrecan deglycosylation;
ARGS assay required aggrecan deglycosylation in
bovine and human measurements but not rat
(that lacks KS residues).
Sandwich ELISAs with anti-HABR
antibody (Invitrogen CAHP0022,
Carlsbad, CA, USA) coupled with
anti-NITEGE (681-3 antibody) or
anti-ARGS (BC3 antibody).
Swearingen 201021 Yes e Baseline, 2
and 4 weeks
42 individuals (14/group) with no,
mild or moderate OA on clinical
exams & radiographic analysis of
knee, hip and spine
Development of an optimized anti-ARGS
antibody (BC3-C2) able to detect aggrecan
neoepitope in human cartilage explant
culture media and human serum, urine
and synovial ﬂuid (that does not require
sample deglycosylation).
Sandwich ELISA with BC3-C2 capture
and anti-HABR detection antibodies.
Duﬁeld 201022 No 113 OA patients with symptoms
(n ¼ 65), knee/hip (n ¼ 30), or
hand/spine (n ¼ 18), and a no OA
reference control group (n ¼ 12);
additional group (overlap with
ﬁrst group not speciﬁed) of 40
healthy controls and 40 OA patients
D Description of development of a sensitive
immunoafﬁnity-based liquid chromatography-
tandem mass spectrometry method to detect
aggrecan cleavage by aggrecanases and
metalloproteinases; ﬁrst report of detection of
aggrecanase-generated ARGS neoepitope
in urine; method worked on human urine
and synovial ﬂuid and several other species
(rat, dog, and bovine); pilot results showed
higher levels in OA patients than controls
and an ARGS/AGEG ratio in synovial ﬂuid
of OA joints of 19.
Immunoafﬁnity based on BC3 anti-ARGS
antibody23; and an in-house polyclonal
antibody to the 1820AGEG epitope
of aggrecan24.
Incident OA
Ling 20096 Up to 10 years
(9.3e11.9 years)
Nested case-control study within the
Baltimore Longitudinal Study of
Aging e 22 incident cases of knee
OA and 66 age, sex and body mass
index matched controls
P Tested 169 proteins using 20 mL of serum;
identiﬁed 10 differentially expressed OA
predictive proteins (IL-15, MMP-7, PAI-1,
VAP-1, DD5, DD6, Eot-2, ICAM-1, MMP-2, P-selectin)
and 16 differentially expressed OA associated
proteins (present at the time of OA diagnosis
of IL-15, MMP-7, PAI-1, VAP-1, 6Ckine, BLC,
FGF-7, GM-CSF, ICAM-3, IGFBP-2, IL-1a, IL-2,
MIP-1a, NT-4, TIMP1, VE-cadherin).
Antibody-based microarrays using
Rolling Circle Ampliﬁcation assays
of Molecular Staging, Inc.
Golightly 20107 Average follow-up
6 years
542 knees were at risk for incident
OA by KL grades (KL grade
of 0e1 at baseline), 349 knees at
risk for incident OST formation
(OST ¼ 0 at baseline), and 440
knees at risk for incident JSN
(JSN ¼ 0 at baseline)
P In adjusted models (age, gender, BMI, bilateral
clustering of knees), the hazard of incident knee
OST and incident JSN increased with higher
baseline COMP levels. The hazard of only
incident knee JSN increased with higher
HA levels. Baseline CRP and KS did not
predict incident knee outcome.
COMP (in-house ELISA with 16F12 and
17C10 monoclonal antibodies25);
HA (Corgenix, Westminster, CO, USA);
hsCRP (UBI Magiwel Enzyme Immunoassay,
United Biotech Inc. Mountain View, CA,
USA); KS (in-house competitive ELISA
with 5D4 monoclonal antibody26).
(continued on next page)
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Table I (continued )
References Follow-up Population/controls (N) BIPEDS Results description and comments Assay
OA subtypes
Filkova 200927 e
Hand OA
Yes e Baseline blood
& bone scintigraphy;
hand X-rays
at baseline and 2 years
55 erosive and 33 non-erosive
hand OA female patients
B, P Serum HA correlated with age and disease duration of hand
OA but not BMI nor treatment with NSAIDs; baseline serum
HA was higher in erosive than non-erosive hand OA
groups, correlated with number of hand joint deformities,
correlated with Kallman radiographic hand OA scores
(at baseline and follow-up), and correlated with level of
hand joint bone remodeling by late phase bone
scintigraphy but not with numbers of inﬂamed
joints by blood pool phase bone scintigraphy; CRP
was neither elevated not associated with
scintigraphic ﬁndings.
HA (Corgenix, USA); CRP (immuno-
tubidimetric technique, biochemical
analyzer Olympus 400, Japan).
Goekoop 201028 e Hand,
hip or knee OA
Yes e Blood at age 85 and
86 years; radiographs
at age 90 years
82 individuals from the
Leiden 85-plus Study
D Low innate production of IL-1b and IL-6 upon whole
blood stimulation (4 h vs 24 h not speciﬁed) with
LPS was associated with increased likelihood of being
“free from OA” (no radiographic hip or knee OA deﬁned
as KL < 2 and no more than two hand joints with
radiographic OA); low innate IL-6 and IL-1Ra associated
with lack of hand OA; low innate IL-1b associated
with lack of hip OA; no associations for TNF-a or IL-10.
Morning blood: cytokine analysis by
non-speciﬁed commercially available
ELISAs performed in a central laboratory.
Rousseau 201029 e
Knee OA
No 64 osteogenesis imperfecta
patients and 64 healthy
age-matched controls; 87
knee OA patients and 291
age-matched controls
D Both osteogenesis imperfecta (OI) and knee OA
associated with elevated CTX-II as well as lower
type I collagen maturation (a/bCTXI ratio) indicative
of turnover of recently synthesized collagen I, i.e.,
‘lower type-I collagen maturation’; results suggest
cartilage degradation related to bone resorption
but causality could not be inferred from this
cross-sectional study; Helix-I was higher in OI
but not OA patients compared with controls.
Urinary a and bCTXI and CTX-II (IDS,
Boldon, UK); urinary Helix-I (Metra,
Quidel Corp, Mountain View, CA, USA).
Chayanupatkul
201030 e Knee OA
No 36 knee OA patients and
15 healthy controls
(all non-diabetic)
B Plasma sRAGE was signiﬁcantly lower in OA
patients than in healthy controls; sRAGE in
plasma and synovial ﬂuid was inversely
correlated with knee OA severity, possibly
due to decreased production or increased
consumption or clearance of sRAGE with disease
severity; sRAGE in plasma correlated with and
was higher than paired synovial ﬂuid concentrations.
sRAGE (Quantikine ELISA, R&D
Systems, MN, USA).
Tissue localization
Liphardt 20099 Yes e 2 weeks Eight young (mean age
26 years) healthy males
I Crossover trial of vibration therapy for immobilization:
14 days of 6 degree head-down-tilt with or
without twice daily whole body vibration
(5 min); serum COMP declined 10e15% during
bedrest despite vibration; serum COMP declined
within 24 h of bedrest and returned to baseline
within 24 h of recovery; MRI cartilage thickness
of the weight bearing tibia decreased 8% following
control intervention and increased 22% following
vibration intervention but portent of this is unknown.
Fasting blood: COMP (AnaMar Medical AB,
Sweden).
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V.B. Kraus / Osteoarthritis and Cartilage 19 (2011) 346e353 351immobilization were separated by a recuperation period of 5 1/2
months. Serum COMP decreased continuously throughout the
bedrest period (with or without vibration), but returned acutely,
within 24 h of resuming activity, back to its constitutive levels in
the adaptation period. The average cartilage thickness increased by
21.9% with vibration, and decreased 8% in the control (non-vibra-
tion) phase relative to the adaptation period. The biomarker results
would suggest that both structural outcomes may be deleterious,
the increase in cartilage volume possibly representing cartilage
swelling and the decrease, cartilage atrophy or degradation. The
papers by Helmark10,11 evaluated the production of biomarkers at
a local level by microdialysis after an acute bout of activity vs
immobilization, by placing two catheters into the knee joints, one
intraarticular and the second perisynovial. Microdialysis was per-
formed by perfusing the catheters slowly with liquid; epitopes of
interest diffused into the tubing from the surrounding region and
could be measured in the dialysate that ﬂowed through the cath-
eter. COMP increased immediately after exercise (leg extensions)
and dropped during the subsequent period of immobilization (3 h
after leg extensions). Intraarticular levels of COMPwere twice those
of the perisynovial tissue and comparable to serum levels. These
studies showed consistent effects of activity and immobilization on
COMP and provided some of the ﬁrst evidence to elucidate the
potential speciﬁc joint-site contributions to the systemic concen-
trations of biomarkers.
Finally there has been substantial progress in the last year related
to the aggrecanase-generated neoepitope biomarker assays,
summarized in an editorial by Fosang12. This has culminated, at long
last, in an ELISA assay sensitive enough to detect an aggrecanase-
generated neoepitope in both human serum and urine13. The BC3
antibody, that detects the aggrecanase-generatedARGSneoepitope in
the aggrecan interglobular domain, was reverse engineered to create
BC3-C2;BC3-C2 ismuchmore sensitive for theARGSneoepitope,with
a 10,000-fold increased afﬁnity over BC3, and unlike the parent
antibody, does not require aggrecan deglycosylation, thereby less-
ening the samplemanipulation that could potentially cause loss of the
epitope. This is a very exciting development in that it has enabled
detection of the aggrecanase-generated neoepitope for the ﬁrst time
in human serum and urine, and could therefore greatly facilitate
patient selection, and dose setting, and provide an early indication of
drug activity in clinical trials that target aggrecan degradation.
In the last year, Aebersold14 depicted the biomarker develop-
ment process as consisting of steps such as sample handling,
complexity reduction, chromatography, mass spectrometry, and
bioinformatics. Two pathways of biomarker qualiﬁcation were
depicted as two trails up a mountain, one a ‘guided and targeted
trail’ representing the process of validating and qualifying candi-
date biomarkers, and the other a ‘discovery trail’ representing an
unbiased approach to the identiﬁcation of biomarkers. Although
the latter was depicted as the trail at the ‘higher altitude’, both trails
were long and arduous with plenty of mountain to tackle, which I
take as plenty of room for discovery and improvement of
biomarkers for disease detection, prognosis and monitoring. I also
like this analogy as it engenders thoughts of a steady march and
a prospect of exciting vistas ahead. In summary, as the qualiﬁcation
of biomarkers yields more speciﬁc and/or more sensitive
biomarkers, it is expected that clinical applicability will become
increasingly feasible, and, as stated at the outset, transition from
the realm of the plausible to the realm of the practical.
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